The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review

Cover Page

Cite item

Full Text

Abstract

Dysimmune neuropathies are heterogeneous group of acquired immune-mediated diseases, accompanied by damage to the peripheral nervous system. As a standard therapy, prednisolone and intravenous immunoglobulins are used. Also encouraging efficacy is demonstrated by the use of a genetically engineered chimeric monoclonal antibody to the CD20 antigen found on the surface of normal and malignant B-cells – rituximab. Rituximab shows encouraging results. We reviewed the use of rituximab for dysimmune polyneuropathies and described our experience in administration of Lewis–Sumner syndrome and myelin-associated glycoprotein related neuropathy with rituximab.

About the authors

V. N. Kiselev

Russian national Center for Emergency and Radiation Medicine n. a. A. M. Nikiforova

Author for correspondence.
Email: kiselev.neurologist@gmail.com
ORCID iD: 0000-0002-6752-3311
54 Optikov St., Saint-Peterburg 197374, Russia Russian Federation

V. G. Potapenko

City Clinical Hospital № 31

Email: fake@neicon.ru
ORCID iD: 0000-0003-2985-0503
3 Dinamo Prospect, Saint-Peterburg 197110, Russia Russian Federation

References

  1. Mathey E.K., Park S.B., Hughes R.A.C. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 2015;86(9):973–85. doi: 10.1136/jnnp-2014-309697. PMID: 25677463.
  2. Suponevа N.А., Naumovа E.S., Gnedovskaya E.V. Chronic inflammatory demyelinating polyneuropathy in adults: diagnostic approaches and first line therapy. Nervnomyshechnye bolezni = Neuromuscular Diseases. 2016;6(1):44-53. (In Russ.).doi: 10.17650/2222-8721-2016-6-1-44-53.
  3. Gazzola S., Delmont E., Franques J. et al. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy. J Neurol Sci 2017;377:144–8. doi: 10.1016/j.jns.2017.04.015. PMID: 28477685.
  4. Yakovlev A.A., Gapeshin R.A., Smochilin A.G., Yakovleva M.V. Evaluation of human immunoglobulin effectiveness in patients with sensory-motor polyneuropathy associated with monoclonal gammapathy of undetermined significance. Arkhiv vnutrenney mediciny = The Russian Archives of Internal Medicine 2018;8(4):278–84. (In Russ.). doi: 10.20514/2226-6704-2018-8-4-278-284.
  5. Ginzberg M.A., Varlamova E.Yu., Ryzhko V.V. et al. Clinical and neurophysiological study of chronic demyelinating polyneuropathy associated with monoclonal secretion. Medicinskiy sovet = Medical Council 2015;10:93–6. (In Russ.).
  6. Suponeva N.A., Nikitin S.S., Varlamova E.Yu. et al. Monoclonal gammopathy in the structure of chronic sensorimotor polyneuropathy of unknown origin: laboratory diagnostics. Vrach = Physician 2010;11:70–2. (In Russ.).
  7. Muley S.A., Parry G.J. Inflammatory demyelinating neuropathies. Curr Treat Options Neurol 2009;11:221–7. doi: 10.1007/s11940-009-0026-4. PMID: 19364457.
  8. Knecht H., Baumberger M., Tobòn A., Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology 2004;63(4):730–2. doi: 10.1212/01.WNL.0000134606.50529.C7. PMID: 15326255.
  9. Bodley-Scott D.D. Chronic inflammatory demyelinating polyradiculoneuropathy responding to rituximab. Pract Neurol 2005;5:242–5. doi: 10.1111/j.1474-7766.2005.00328.x.
  10. Gorson K.C., Natarajan N., Ropper A.H. et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial. Muscle Nerve 2007:35(1):66–9. doi: 10.1002/mus.20664. PMID: 16967492.
  11. Münch C., Anagnostou P., Meyer R., Haas J. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 2007;256(1–2):100–2. doi: 10.1016/j.jns.2007.02.027. PMID: 17382963.
  12. Sadnicka A., Reilly M.M., Mummery C. et al. Rituximab in the treatment of three coexistent neurological autoimmune diseases: Chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82(2):230–2. doi: 10.1136/jnnp.2009.174888. PMID: 20462915.
  13. Benedetti L., Briani C., Franciotta D. et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: A report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011;82(3):306–8. doi: 10.1136/jnnp.2009.188912. PMID: 20639381.
  14. Querol L., Rojas-García R., Diaz-Manera J. et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015;2(5):e149. doi: 10.1212/NXI.0000000000000149. PMID: 26401517.
  15. Renaud S., Gregor M., Fuhr P. et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27(5):611–5. doi: 10.1002/mus.10359. PMID: 12707982.
  16. Broglio L., Lauria G. Worsening after rituximab treatment in anti-MAG neuropathy. Muscle Nerve 2005;32(3):378–9. doi: 10.1002/mus.20386. PMID: 15986418.
  17. Renaud S., Fuhr P., Gregor M. et al. High-dose rituximab and anti-MAG–associated polyneuropathy. Neurology 2006;66(5):742–4. doi: 10.1212/01.wnl.0000201193.00382.b3. PMID: 16534115.
  18. Benedetti L., Briani C, Grandis M. et al. Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007;12:102–7. doi: 10.1111/j.1529-8027.2007.00129. x. PMID: 17565535.
  19. Zara G., Zambello R., Ermani M. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy. Clin Neurophysiol 2011;122(12):2518–22. doi: 10.1016/j.clinph.2011.05.015. PMID: 21680240.
  20. Dalakas M.C., Rakocevic G., Salajegheh M. et al. Placebo-controlled trial of rituximab in IgM anti-myelinassociated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65(3):286–93. doi: 10.1002/ana.21577. PMID: 19334068.
  21. Léger J.M., Viala K., Nicolas G. et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 2013;80(24):2217–25. doi: 10.1212/WNL.0b013e318296e92b. PMID: 23667063.
  22. Campagnolo M., Zambello R., Nobile-Orazio E. et al. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. J Neurol Neurosurg Psychiatry 2017;88:1094–7. doi: 10.1136/jnnp-2017-315736. PMID: 28501820.
  23. Attarian S.,Verschueren A., Franques J. et al. Response to treatment in patients with Lewis-Sumner syndrome. Muscle Nerve 2011;44(2):179–84. doi: 10.1002/mus.22024.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Kiselev V.N., Potapenko V.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 85909 от  25.08.2023.